The Three-Amino-Acid Peptide KPV Reduced Intestinal Inflammation in Two Mouse Models of IBD
KPV, a tripeptide derived from alpha-MSH, significantly reduced inflammation in two different mouse models of inflammatory bowel disease, with faster weight recovery, lower inflammatory cell infiltration, and reduced tissue damage.
Quick Facts
What This Study Found
In the DSS-colitis model, KPV treatment led to significantly earlier recovery and stronger body weight regain compared to controls (p<0.01). Inflammatory cell infiltration was significantly reduced (p<0.05). In the adoptive transfer model (a T cell-driven colitis that more closely mimics human IBD), KPV-treated mice had significantly lower clinical scores, less body weight loss, and lower grades of tissue inflammation on histology.
In vitro, KPV inhibited TNF-alpha-induced IL-8 secretion in intestinal epithelial cells, demonstrating a direct anti-inflammatory mechanism at the cellular level.
Key Numbers
Body weight regain P<0.01; inflammatory infiltrates P<0.05; lower clinical scores in adoptive transfer model
How They Did This
Two murine colitis models were used: DSS-induced colitis (chemical injury model) and T cell adoptive transfer colitis (immune-mediated model). KPV was administered intraperitoneally. Outcomes measured included body weight changes, clinical scores, and histological assessment of tissue inflammation. In vitro experiments tested KPV's effect on TNF-alpha-induced IL-8 secretion in intestinal epithelial cells.
Why This Research Matters
Inflammatory bowel disease (Crohn's and ulcerative colitis) affects millions of people, and current treatments often have significant side effects. KPV's anti-inflammatory effects in two mechanistically different colitis models — one driven by chemical injury, one by immune cells — suggests broad applicability. Its tiny size (just 3 amino acids) makes it potentially easier and cheaper to produce than full-length protein therapies.
The Bigger Picture
This 2008 study is one of the foundational papers supporting KPV's potential for IBD treatment. It demonstrated that you don't need the full alpha-MSH molecule — just its three C-terminal amino acids retain anti-inflammatory activity in the gut. This has fueled ongoing interest in KPV for gut health, though human clinical trials have not yet been conducted. The study also supports the broader concept that small peptide fragments of larger hormones can be therapeutically useful.
What This Study Doesn't Tell Us
Both models are murine (mouse), and results may not translate directly to human IBD. KPV was administered intraperitoneally (injected into the abdomen), not orally, so oral bioavailability wasn't tested. Specific dosing details and exact group sizes are not provided in the abstract. No human clinical trial data exists for KPV in IBD.
Questions This Raises
- ?Would oral KPV be effective for colitis, or does it need to be injected to reach the intestinal tissue?
- ?How does KPV compare to existing IBD medications like anti-TNF biologics in terms of efficacy?
- ?Could KPV be delivered locally to the colon via encapsulation to maximize gut exposure while minimizing systemic effects?
Trust & Context
- Key Stat:
- Effective in 2 mechanistically different IBD models KPV worked in both chemical-injury (DSS) and immune-driven (adoptive transfer) colitis, suggesting broad anti-inflammatory potential in the gut
- Evidence Grade:
- This is a preclinical animal study using two established murine colitis models plus in vitro cell experiments. It provides moderate-strength evidence supporting KPV's anti-inflammatory potential but has not been tested in humans.
- Study Age:
- Published in 2008, this is one of the earliest studies demonstrating KPV's efficacy in IBD models. It remains highly cited and is foundational to the KPV gut health research area.
- Original Title:
- Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
- Published In:
- Peptides, 29(12), 2137-46 (2008)
- Authors:
- Kannengiesser, K, Maaser, C, Heidemann, J, Luegering, A, Ross, M, Brzoska, T, Böhm, M, Luger, T A, Domschke, W, Kucharzik, T
- Database ID:
- RPEP-01362
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is KPV and where does it come from?
KPV is a tripeptide (three amino acids: lysine-proline-valine) that comes from the tail end of alpha-MSH, a natural hormone your body produces. While alpha-MSH has many effects including skin tanning and appetite regulation, KPV specifically retains its anti-inflammatory properties in a much smaller, simpler package.
Could KPV eventually be used to treat Crohn's disease or ulcerative colitis?
The mouse data is promising — KPV worked in two different colitis models. However, human clinical trials haven't been conducted yet. Key challenges include determining the best delivery route (oral vs. injection vs. local), optimal dosing, and whether the effects seen in mice translate to human IBD.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-01362APA
Kannengiesser, K; Maaser, C; Heidemann, J; Luegering, A; Ross, M; Brzoska, T; Böhm, M; Luger, T A; Domschke, W; Kucharzik, T. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.. Peptides, 29(12), 2137-46. https://doi.org/10.1016/j.peptides.2007.10.012
MLA
Kannengiesser, K, et al. "Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.." Peptides, 2008. https://doi.org/10.1016/j.peptides.2007.10.012
RethinkPeptides
RethinkPeptides Research Database. "Melanocortin-derived tripeptide KPV has anti-inflammatory po..." RPEP-01362. Retrieved from https://rethinkpeptides.com/research/kannengiesser-2008-melanocortinderived-tripeptide-kpv
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.